Ted Slocomb

Mr. Slocomb joined Bear Stearns Health Innoventures from the CNS/Metabolic Franchise of Ortho-McNeil Pharmaceutical, a division of Johnson & Johnson.
At Ortho-McNeil Pharmaceutical, his responsibilities included new product planning and commercial evaluations of product acquisition and in-licensing opportunities in metabolic disease as well as lifecycle management initiatives in neurology.
Prior to BASF Pharma, at Bogart Delafield Ferrier, Mr. Slocomb was a strategy consultant to leading pharmaceutical and biopharmaceutical companies, including Genentech, Pfizer, Hoechst Marion Roussel, GlaxoWellcome, SmithKline Beecham, and Bristol-Myers Squibb.
Assignments included product launch and marketing strategy formulation, repositioning of under-performing products, R&D portfolio evaluation and prioritization, post-acquisition integration of R&D assets and technology in-licensing/acquisition screening and assessment.
Mr. Slocomb earned a BA in Genetics from the University of California at Berkeley and an MBA in Finance from the Stern School of Business at New York University (Stern Scholar, Beta Gamma Sigma).